Living Donor Liver Transplantation for Hepatocellular Carcinoma

Basit Öğe Kaydı
dc.authoridince, volkan/0000-0002-0714-490X
dc.authoridYilmaz, Sezai/0000-0002-8044-0297
dc.authoridKayaalp, Cuneyt/0000-0003-4657-2998
dc.authorwosidKayaalp, Cuneyt/AAH-1764-2021
dc.authorwosidince, volkan/M-7325-2017
dc.authorwosidYilmaz, Sezai/ABI-2323-2020
dc.authorwosidAbecassis, Michael m i/F-7977-2011
dc.contributor.authorIsik, B.
dc.contributor.authorInce, V.
dc.contributor.authorKarabulut, K.
dc.contributor.authorKayaalp, C.
dc.contributor.authorYilmaz, S.
dc.date.accessioned2024-08-04T20:36:02Z
dc.date.available2024-08-04T20:36:02Z
dc.date.issued2012
dc.departmentİnönü Üniversitesien_US
dc.description8th Congress of the Turkish-Transplantation-Centers-Coordination-Association (TTCCA) -- OCT 12-16, 2011 -- Antalya, TURKEYen_US
dc.description.abstractBackground. Liver transplantation is a widely accepted modality in the treatment of hepatocellular carcinoma (HCC). In our center, patients with HCC limited to the liver without macrovascular invasion are accepted as candidates for living donor liver transplantation (LDLT). The aim of this study was to describe the patient characteristics and outcomes at a single institution to analyze the impact of our criteria on the survival of HCC patients. Patients and Methods. We reviewed the medical records of all HCC (n = 105) patients who underwent liver transplantation in our institution. We excluded deaths in the early postoperative period and deceased donor liver transplantation (DDLT) patients, leaving 74 subjects (65 males and 9 female). Their median age was 53 years (range, 19-69). Univariate Kaplan-Meier and multivariate Cox proportional hazards models were used to analyze overall and disease-free survivals. Results. Thirty-two (43%) patients were within the Milan criteria, and 42 (57%) exceeded them. One- and 2-year overall survival rates for patients within versus exceeding the Milan criteria were 72% versus 68% and 61% versus 58%, respectively. One- and 2-year disease-free survival rates for patients within versus exceeding the Milan criteria were 72% versus 68% and 60% versus 55%, respectively (P > .05). Tumor recurrence rates for patients within versus exceeding the Milan criteria were 0% versus 36%, respectively (P = .0002). Alpha-fetoprotein level was the only predictor of overall survival; alpha-fetoprotein level and tumor differentiation were predictors of disease-free survival. Conclusion. Although higher recurrence rates have been observed among patients exceeding the Milan criteria, LDLT is the only treatment option for the patients in countries with limited sources of cadaveric organs. As a general principle, we believe that the use of cadaveric donor liver grafts is not suitable for patients who exceed these criteria.en_US
dc.description.sponsorshipTurkish Transplantat Ctr Coordinat Assoc (TTCCA)en_US
dc.identifier.doi10.1016/j.transproceed.2012.05.033
dc.identifier.endpage1716en_US
dc.identifier.issn0041-1345
dc.identifier.issue6en_US
dc.identifier.pmid22841251en_US
dc.identifier.scopus2-s2.0-84864404702en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage1713en_US
dc.identifier.urihttps://doi.org/10.1016/j.transproceed.2012.05.033
dc.identifier.urihttps://hdl.handle.net/11616/95748
dc.identifier.volume44en_US
dc.identifier.wosWOS:000307433400066en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherElsevier Science Incen_US
dc.relation.ispartofTransplantation Proceedingsen_US
dc.relation.publicationcategoryKonferans Öğesi - Uluslararası - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectAdult Patientsen_US
dc.subjectExperienceen_US
dc.titleLiving Donor Liver Transplantation for Hepatocellular Carcinomaen_US
dc.typeConference Objecten_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu